Alzheimer’s Disease and Paraoxonase 1 (PON1) Gene Polymorphisms

Background: Some studies have indicated that human paraoxonase 1 (PON1) activity shows a polymorphic distribution. The aim of this study was to determine the distribution of PON1 polymorphism in patients with Alzheimer’s disease in Gorgan and compare it with a healthy control group. Method: The study included 100 healthy individuals and 50 patients. Enzyme activity and genetic polymorphism of PON1 were determined. Result: There were significant differences in distribution of genotypes and alleles among patients and control group. The most common genotype was CT in patients and control group, while the most frequent alleles were T and C in patients and controls, respectively. There was a statistically significant variation between serum PON1 activity and –108C> T polymorphism. The highest PON1 enzyme activities in the patients and controls were found in CC, while lower enzyme activities were seen in CT and TT genotypes in both genders and age groups. Conclusion: Onset of Alzheimer’s disease may depend on different polymorphisms of the PON1 enzyme. Late or early-onset of Alzheimer’s disease may also depend on age and gender distribution, especially for arylesterase enzyme. Further studies on polymorphism of the enzyme are necessary for interpretation of possible polymorphic effects of enzyme on PON1 activity in humans.

[1]  D. Ryglewicz,et al.  Paraoxonase 1 (PON1) gene-108C>T and p.Q192R polymorphisms and arylesterase activity of the enzyme in patients with dementia. , 2013, Folia neuropathologica.

[2]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[3]  P. Amouyel,et al.  Paraoxonase 1 gene polymorphisms and dementia in humans , 2004, Neuroscience Letters.

[4]  A. Motulsky,et al.  Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon. , 1988, American journal of human genetics.

[5]  Yongyong Shi,et al.  Association between paraoxonase gene and stroke in the Han Chinese population , 2013, BMC Medical Genetics.

[6]  R. Tanzi.  The genetics of Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[7]  A. Égerházi,et al.  Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia , 2002, European Archives of Psychiatry and Clinical Neuroscience.

[8]  A. Motulsky,et al.  Plasma paraoxonase polymorphism: a new enzyme assay, population, family, biochemical, and linkage studies. , 1983, American journal of human genetics.

[9]  A. Gugliucci,et al.  Paraoxonase 1 in neurological disorders , 2014, Redox report : communications in free radical research.

[10]  J. Marrugat,et al.  [The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis]. , 2004, Revista espanola de cardiologia.

[11]  G. Jickling,et al.  Ischemic stroke biomarkers in blood. , 2013, Biomarkers in medicine.

[12]  W. Pardridge,et al.  IgG-paraoxonase-1 fusion protein for targeted drug delivery across the human blood-brain barrier. , 2008, Molecular pharmaceutics.

[13]  J. Joven,et al.  Paraoxonases as Potential Antibiofilm Agents: Their Relationship with Quorum-Sensing Signals in Gram-Negative Bacteria , 2011, Antimicrobial Agents and Chemotherapy.

[14]  O. Lindvall,et al.  Inhibition of Microglial Activation Protects Hippocampal Neurogenesis and Improves Cognitive Deficits in a Transgenic Mouse Model for Alzheimer’s Disease , 2012, Neurodegenerative Diseases.

[15]  L. Costa,et al.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on. , 2011, Biochemical pharmacology.

[16]  R. Armstrong.  β-amyloid (Aβ) deposition in cognitively normal brain, dementia with Lewy bodies, and Alzheimer's disease: a study using principal components analysis. , 2012, Folia neuropathologica.

[17]  M. Kobayashi,et al.  Lactone-ring-cleaving enzyme: genetic analysis, novel RNA editing, and evolutionary implications. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[18]  D. Ryglewicz,et al.  Paraoxonase activity and dementia , 2009, Journal of the Neurological Sciences.

[19]  P. Froguel,et al.  Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.

[20]  J. Gazewood,et al.  Parkinson disease: an update. , 2013, American family physician.

[21]  Tatiana Foroud,et al.  Genetics of Parkinson disease , 2004, Genetics in Medicine.

[22]  Ken Arai,et al.  Pathophysiologic Cascades in Ischemic Stroke , 2012, International journal of stroke : official journal of the International Stroke Society.

[23]  P. Peeters,et al.  Genetic and environmental determinants of the PON‐1 phenotype , 2007, European journal of clinical investigation.

[24]  J. Landers,et al.  Paraoxonase 1 (PON1) organophosphate hydrolysis is not reduced in ALS , 2008, Neurology.

[25]  M. Mackness,et al.  Targeting paraoxonase-1 in atherosclerosis , 2013, Expert opinion on therapeutic targets.

[26]  C. Carlson,et al.  Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[27]  P. Froguel,et al.  Promoter polymorphism T(-107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. , 2000, Diabetes.

[28]  B. La Du,et al.  Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[29]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[30]  O. Hanon,et al.  Vascular risk factors, cognitve decline, and dementia , 2008, Vascular health and risk management.

[31]  E. Niki,et al.  Proteomic characterization of oxidative dysfunction in human umbilical vein endothelial cells (HUVEC) induced by exposure to oxidized LDL , 2005, Free radical research.

[32]  Z. Stelmasiak,et al.  Paraoxonase 1 activity in different types of multiple sclerosis , 2009, Multiple sclerosis.

[33]  J. Lambert,et al.  Association study of the paraoxonase 1 gene with the risk of developing Alzheimer's disease , 2009, Neurobiology of Aging.

[34]  G. Getz,et al.  Paraoxonase, a cardioprotective enzyme: continuing issues , 2004, Current opinion in lipidology.

[35]  I. Leviev,et al.  Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[36]  R. Mayeux,et al.  Epidemiology of Alzheimer disease , 2011, Nature Reviews Neurology.

[37]  G. Franceschini,et al.  Enzymatically Active Paraoxonase-1 Is Located at the External Membrane of Producing Cells and Released by a High Affinity, Saturable, Desorption Mechanism* , 2002, The Journal of Biological Chemistry.

[38]  M. Cogné,et al.  Paraoxonase 1 192/55 Gene Polymorphisms in Alzheimer's Disease , 2002, Annals of the New York Academy of Sciences.

[39]  D. Cutler,et al.  Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases , 2012, Neurobiology of Aging.

[40]  A. Tsatsakis,et al.  Role of paraoxonase 1 (PON1) in organophosphate metabolism: implications in neurodegenerative diseases. , 2011, Toxicology and applied pharmacology.

[41]  S. Sorbi,et al.  Association analysis of the paraoxonase-1 gene with Alzheimer's disease , 2006, Neuroscience Letters.

[42]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[43]  Shuran Li,et al.  Prevalence of dementia in Latin America, India, and China: a population-based cross-sectional survey , 2008, The Lancet.

[44]  M. Aviram,et al.  Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion , 2013, Current opinion in lipidology.

[45]  A. Słowik,et al.  Paraoxonase 1 Gene Polymorphisms Do Not Influence the Response to Treatment in Alzheimer’s Disease , 2011, Dementia and Geriatric Cognitive Disorders.

[46]  S. Reddy,et al.  Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein* , 2001, The Journal of Biological Chemistry.

[47]  D. Holtzman,et al.  Deciphering Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[48]  M. Mackness,et al.  Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? , 2004, Free radical biology & medicine.

[49]  P. Durrington,et al.  Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation , 1999, The Lancet.

[50]  R. Bernabei,et al.  Lack of Association between Alzheimer’s Disease and Gln-Arg 192 Q/R Polymorphism of the PON-1 Gene in an Italian Population , 2003, Dementia and Geriatric Cognitive Disorders.

[51]  R. James,et al.  Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[52]  Kai Chang,et al.  Lack of an association between Paraoxonase 1 gene polymorphisms (Q192R, L55M) and Alzheimer's disease: A meta-analysis , 2012, Neuroscience Letters.

[53]  G. Zuliani,et al.  Genetic polymorphisms in older subjects with vascular or Alzheimer's dementia , 2001, Acta neurologica Scandinavica.

[54]  M. Aviram,et al.  Paraoxonase 1 (PON1) reduces macrophage inflammatory responses. , 2013, Atherosclerosis.

[55]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[56]  De-Pei Liu,et al.  Paraoxonase gene polymorphisms, oxidative stress, and diseases , 2003, Journal of Molecular Medicine.

[57]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.